Publications by authors named "T Kasuya"

Chronic nerve compression disorders, such as carpal tunnel syndrome, are common and can significantly impair daily activities due to motor and sensory dysfunctions. Currently, no systemic pharmacotherapy exists for preventing or treating disease progression. This study aims to investigate whether Neurotropin®, an established analgesic, has therapeutic effects.

View Article and Find Full Text PDF

Postoperative adhesion around nerves sometimes results in sensory and motor dysfunctions. To prevent these disorders, we have developed an electrospun nanofiber sheet incorporating methylcobalamin (MeCbl), an active form of vitamin B12 with anti-inflammatory and neuroregenerative effects. This study aimed to investigate the neuroprotective effects of MeCbl sheets against postoperative adhesion and to compare the effects of MeCbl sheets with those of porcine small intestinal submucosa (SIS) sheets using a rat sciatic nerve adhesion model.

View Article and Find Full Text PDF

The discovery of novel natural products through the exploration of distinct microorganisms is crucial for advancing drug discovery research. In this study, we focus on a unique environmental resource, microbial masses known as "Tengu-no-Mugimeshi." From the culture broth of Lecanicillium aphanocladii FKI-9593, isolated from Tengu-no-Mugimeshi collected at Mount Kurohime, Nagano Prefecture, Japan, we report the isolation of two novel tetrapeptides, tengupeptins A (1) and B (2), as well as the known compound oosporein.

View Article and Find Full Text PDF

(≡ ), known as the mulberry rust which is an anamorphic rust fungus forming only aecidioid uredinia, were found on in Ibaraki and Saitama Prefectures, Japan. Molecular phylogenetic analyses using the combined dataset of sequences from 28S and 18S of the nuclear ribosomal RNA gene and Cytochrome-c-oxidase subunit 3 of the mitochondrial DNA revealed that this anamorphic rust fungus was a member of the clade composed of the genus . Therefore, a new combination, is proposed for this species.

View Article and Find Full Text PDF

Background And Aims: Guillain-Barré syndrome (GBS) is an acute, self-limited, immune-mediated peripheral neuropathy. Current treatments for GBS include intravenous immunoglobulin (IVIg) and plasma exchange, which may not sufficiently benefit severely affected patients. This study evaluated the efficacy and safety of eculizumab add-on therapy to IVIg (standard-of-care treatment) in patients with severe GBS.

View Article and Find Full Text PDF